Addendum
Cabozantinib (renal cell carcinoma) - Addendum to Commission A18-37
Report documents
-
Addendum
Cabozantinib (renal cell carcinoma) - Addendum to Commission A18-37
Dossier assessment
Indication:
Treatment-naive adults with advanced renal cell carcinoma (intermediate or poor risk)
Result of dossier assessment:
Conclusion of dossier assessment A18-37 unchanged
Additional information
Federal Joint Committee (G-BA)
2018-12-06 A G-BA decision was published.
Project details
- Project no.
- A18-70
- Commission
- Commission awarded on 22.10.2018 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Connected Projects
-
Dossier assessment
Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed